You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Shota Sakaue1, Michihisa Kono1, Takumi Kumai1,2
1Department of Otolaryngology Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa 078-8510, Japan.
Perioperative immunotherapy shows promise for resectable head and neck squamous cell carcinoma (HNSCC). While neoadjuvant and adjuvant strategies differ, recent trials support integrating immune checkpoint inhibitors (ICIs) for improved outcomes.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: